A 28-year-old man with newly diagnosed AML-M3 (acute promyelocytic leukemia) presents with fever, petechiae, and gingival bleeding. Coagulation studies show PT 18 s, aPTT 45 s, fibrinogen 80 mg/dL, and D-dimer markedly elevated. Which investigation is most appropriate to confirm the diagnosis of AML-M3 and guide targeted therapy?

Question

Accepted Answer

C. t(15;17) translocation by fluorescence in situ hybridization (FISH) or reverse transcriptase-PCR. ## AML-M3 Diagnosis: Cytogenetic Confirmation Is Essential

**Key Point:** Detection of t(15;17) translocation by FISH or RT-PCR is the most specific and diagnostic investigation for AML-M3 (acute promyelocytic leukemia). This translocation results in the PML-RARA fusion gene, which is:
- Pathognomonic for AML-M3
- Essential for confirming the diagnosis
- Mandatory for initiating all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) therapy
- Used for MRD monitoring during and after treatment

## AML-M3: Diagnostic Approach

```mermaid
flowchart TD
  A[Suspected AML-M3]:::outcome --> B[Morphology: abnormal promyelocytes]:::action
  B --> C{Cytogenetic confirmation}:::decision
  C -->|t15;17 present| D[AML-M3 confirmed]:::outcome
  D --> E[Initiate ATRA + ATO]:::action
  C -->|t15;17 absent| F[Other AML subtype]:::outcome
  F --> G[Standard chemotherapy]:::action
  B --> H[Coagulation studies]:::action
  H --> I[DIC assessment]:::outcome
  I --> J[Supportive care: FFP, platelets]:::action
```

**High-Yield:** AML-M3 is the only acute leukemia with a specific, curative targeted therapy (ATRA + ATO). Cytogenetic confirmation is mandatory before starting treatment. Without t(15;17), the diagnosis is not AML-M3, and ATRA/ATO would be inappropriate.

## Why Cytogenetics Is Diagnostic

| Feature | AML-M3 | Other AML |
|---|---|---|
| **Morphology** | Abnormal promyelocytes with Auer rods | Variable |
| **t(15;17) translocation** | **Pathognomonic (100%)** | Absent |
| **PML-RARA fusion** | **Present** | Absent |
| **Response to ATRA/ATO** | **Excellent (90% CR)** | Not applicable |
| **Cytochemistry** | MPO+, Sudan Black+, PAS+ | Variable |

**Clinical Pearl:** AML-M3 presents with severe disseminated intravascular coagulation (DIC) due to release of procoagulant substances from abnormal promyelocytes. While coagulation studies confirm DIC, they do NOT confirm the diagnosis of AML-M3. Cytogenetic testing is essential.

## Role of Each Investigation

1. **Morphology + cytochemistry:** Suggests AML-M3 (abnormal promyelocytes, MPO+)
2. **Cytogenetics (FISH/RT-PCR):** **Confirms t(15;17) — diagnostic gold standard**
3. **Coagulation studies:** Assesses DIC severity; guides supportive care (FFP, platelets, cryoprecipitate)
4. **Flow cytometry:** Confirms myeloid lineage; not specific for AML-M3

Answer

A. Serum fibrinogen and D-dimer levels

Answer

B. Prothrombin time and activated partial thromboplastin time

Answer

D. Bone marrow cytochemistry with Sudan Black and PAS stains

Explanation

AML-M3 Diagnosis: Cytogenetic Confirmation Is Essential

AML-M3: Diagnostic Approach

Why Cytogenetics Is Diagnostic

Role of Each Investigation

Practice similar questions

Join our NEET PG community

Feature	AML-M3	Other AML
Morphology	Abnormal promyelocytes with Auer rods	Variable
t(15;17) translocation	Pathognomonic (100%)	Absent
PML-RARA fusion	Present	Absent
Response to ATRA/ATO	Excellent (90% CR)	Not applicable
Cytochemistry	MPO+, Sudan Black+, PAS+	Variable